QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Earnings Call Touches On Key Duke Partnership, Planned IND Submission, Double-Digit Q3 Sales Growth 0 comments
    Nov 14, 2013 2:16 PM | about stocks: ISCO

    International Stem Cell Corp. yesterday kicked-off its earnings call, led by the company's executive vice president, Dr. Simon Craw. Among other introductory items, Dr. Craw detailed the company's key clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease.

    Utilizing this agreement, the company in September brought together a team of leading experts to develop techniques and designs as well as to provide guidance for the company's investigational new drug (NYSE:IND) submission to use ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. ISCO plans on submitting its IND to the FDA in 2014.

    "The main person of the agreement was really to tap into Duke's excellence in the fields of clinical neurology and in running early-stage clinical trials, especially trials using stem-cell derived products," said Dr. Craw. "It was important for us to choose a clinical research organization with significant expertise in both cell therapy and in handling stem cells, and over the years, Duke has really built an international reputation in both of these areas."

    The company said it plans to publish all data from its first primate study in peer-reviewed scientific literature before year-end.

    ISCO CFO Jay Novack recapped the company's third-quarter results, first noting the company's double-digit sales growth. ISCO increased revenue 41 percent to $1.67 million, compared to $1.19 million for the corresponding period in 2012. Sales for the company's Lifeline Skin Care (NYSEARCA:LSC) and Lifeline Cell Technology (LCT) units increased by 54 percent and 30 percent, and accounted for 49 percent and 51 percent of total revenue, respectively.

    Dr. Craw concluded the conference call in saying, "I'd like to reiterate that I think we've had an outstanding quarter with just truly excellent revenue growth from both of our commercial businesses and tremendous progress from our R&D organization, and I look forward to talking about the full-year progress when we file our 10-K next year and looking back on a banner year for International Stem Cell."

    A playback of the call will be available until 11:59 pm ET on November 27, 2013. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin 4648561.

    For more information, visit internationalstemcell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.